Strattera (atomoxetine) is FDA-approved to treat one condition: attention-deficit/hyperactivity disorder (ADHD). It is approved for both children ages 6 and older and adults, making it one of the few non-stimulant medications specifically indicated for ADHD across the lifespan. While it only has one official indication, doctors sometimes prescribe it off-label for several other conditions.
How Strattera Works
Strattera is a selective norepinephrine reuptake inhibitor. In plain terms, it increases the amount of norepinephrine available in the brain by preventing nerve cells from reabsorbing it too quickly. Norepinephrine plays a key role in attention, focus, and impulse control, which are the core areas that break down in ADHD.
This mechanism makes Strattera fundamentally different from the stimulant medications most people associate with ADHD treatment, like methylphenidate (Ritalin) or amphetamine-based drugs (Adderall). Stimulants primarily boost dopamine levels and take effect within an hour. Strattera works more gradually, building up in your system over weeks before you feel the full benefit.
ADHD Symptoms It Targets
Strattera’s FDA approval is based on seven clinical trials: four short-term studies in children and adolescents ages 6 to 18, two studies in adults, and one longer-term maintenance study in children ages 6 to 15. Across these trials, it improved the full range of ADHD symptoms, including inattention, hyperactivity, and impulsivity.
In a long-term open-label study following 384 adults for up to 97 weeks, ADHD symptom scores dropped by about 33% from baseline, and the improvement held over time. This suggests Strattera remains effective with continued use rather than losing its impact.
One important note on timing: Strattera is not a medication you take and feel working that same day. Most people need at least 4 weeks at the target dose before they can fairly judge whether it’s helping. Some people notice gradual improvements in focus and impulse control during the first week or two, but the full therapeutic effect takes longer to develop.
Why Some People Choose It Over Stimulants
The biggest practical difference between Strattera and stimulant ADHD medications is abuse potential. In clinical testing, participants rated atomoxetine no more “likeable” than a placebo, while methylphenidate was rated significantly more appealing. Researchers concluded that atomoxetine has significantly less abuse liability than methylphenidate. Because of this, Strattera is not classified as a controlled substance, which means prescriptions are easier to manage. There are no special restrictions on refills, and your doctor can call in prescriptions by phone or send electronic prescriptions without the extra steps required for stimulants.
This makes Strattera a common choice for people with a history of substance use, those who experience anxiety or jitteriness on stimulants, or anyone who prefers a medication with smoother, around-the-clock coverage rather than the peak-and-trough pattern of stimulant dosing. It also provides continuous symptom control, including early morning and late evening, since it doesn’t wear off the way a stimulant dose does.
Off-Label Uses
Because Strattera boosts norepinephrine, a chemical involved in mood, motivation, and cognitive function, researchers and clinicians have explored it for conditions beyond ADHD. None of these uses are FDA-approved, but they show up in clinical practice.
- Depression: Strattera’s norepinephrine-boosting action overlaps with how some antidepressants work. Case reports and small studies have found it helpful both as a standalone treatment and as an add-on for people whose depression hasn’t responded fully to other medications.
- Binge eating disorder: A 10-week randomized, placebo-controlled trial found that atomoxetine significantly reduced binge-eating episodes, body weight, BMI, and overall illness severity compared to placebo. It has also been studied as a possible treatment for obesity.
- Cognitive difficulties in other conditions: Researchers have explored whether Strattera can sharpen thinking and executive function in people with schizophrenia and Parkinson’s disease, where attention and planning are often impaired.
- Substance use: Because it affects norepinephrine without producing a high, Strattera has been studied for possible roles in treating cocaine addiction, marijuana dependence, and smoking cessation. Results are preliminary.
If your doctor suggests Strattera for something other than ADHD, it means they’re drawing on this broader evidence base while using the medication in a way that isn’t part of its official label.
What to Expect When Starting
For adults and adolescents over about 155 pounds (70 kg), the typical starting dose is 40 mg per day, increasing after at least 3 days to a target of 80 mg per day. If that isn’t enough after another 2 to 4 weeks, the maximum dose is 100 mg per day. For smaller children and adolescents, dosing is based on body weight, starting at about 0.5 mg/kg per day and moving up to a target of 1.2 mg/kg, with an absolute ceiling of 100 mg.
You can take Strattera once in the morning or split it into a morning and late afternoon dose. Splitting the dose sometimes helps reduce stomach-related side effects like nausea, which is one of the more common complaints in the first few weeks. Most side effects tend to settle down as your body adjusts.
Unlike stimulants, Strattera is not approved for children under 6. Its safety and effectiveness in that age group have not been studied.
Important Safety Considerations
Strattera carries an FDA boxed warning about an increased risk of suicidal thinking in children and adolescents. This risk was identified in clinical trials and is most relevant during the first few months of treatment or when doses change. It does not mean Strattera commonly causes suicidal behavior, but it does mean that mood and behavior should be monitored closely, especially early on.
Strattera can also raise heart rate and blood pressure modestly. For most people this isn’t clinically meaningful, but it matters if you have an underlying heart condition. Rare cases of liver injury have been reported, so unexplained nausea, dark urine, yellowing skin, or upper-right abdominal pain during treatment warrants prompt medical attention.
People taking a type of antidepressant called an MAOI should not take Strattera. The combination can cause dangerous spikes in blood pressure. A washout period of at least two weeks between stopping one and starting the other is standard practice. Certain other medications that affect the same liver enzyme responsible for breaking down Strattera can also change how much of the drug stays in your system, potentially requiring dose adjustments.